1、What information is needed?

Answer: Preliminary information includes the following points:

(1) Expression target: Protein or antibody.

(2) Provide: Sequence? Mouse hybridoma cell line? Antibody sample?

(3) Sequence route: Gene synthesis, construction of stable expression plasmid, transient transfection test, stable transfection test, stable transfection screening, multi-clone pool, single clone pool, stable transfection strain expression test, delivery.

(4) Mouse hybridoma cell line route: Hybridoma resequencing, gene synthesis, construction of stable expression plasmid, transient transfection test, stable transfection test, stable transfection screening, multi-clone pool, single clone pool, stable transfection strain expression test, delivery.

(5) Antibody sample route: Mass spectrometry sequencing, gene synthesis, construction of stable expression plasmid, transient transfection test, stable transfection test, stable transfection screening, multi-clone pool, single clone pool, stable transfection strain expression test, delivery.

2、Briefly describe the advantages of your company's platform?

Answer: By using a proprietary and modified high-expression CHO cell line, an optimized culture system, and the GS/DHFR selection expression system, we conduct initial transient transfection assessments to ensure subsequent stable monoclonal screening. The most optimal clones are identified through stepwise screening in the cell pool, and candidate single clones are determined. These clones undergo passaging for stability, qualitative and quantitative product control testing, ultimately delivering a single clone cell line that meets customer satisfaction.